Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 426 to 450 of 921

TitleReference numberPublishedLast updated
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancerTA740
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA741
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitableTA739
Tofacitinib for treating juvenile idiopathic arthritisTA735
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapyTA736
Berotralstat for preventing recurrent attacks of hereditary angioedemaTA738
Secukinumab for treating moderate to severe plaque psoriasis in children and young peopleTA734
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA733
Baloxavir marboxil for treating acute uncomplicated influenza in people 12 years and over (terminated appraisal)TA732
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)TA730
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)TA731
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA726
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA727
Midostaurin for treating advanced systemic mastocytosisTA728
Sapropterin for treating hyperphenylalaninaemia in phenylketonuriaTA729
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA725
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancerTA724
Bimekizumab for treating moderate to severe plaque psoriasisTA723
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangementTA722
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndromeTA139
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphomaTA720
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA716
Secukinumab for treating active non-radiographic axial spondyloarthritisTA719
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)TA717
Ixekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritisTA718

Results per page

  1. 10
  2. 25
  3. 50
  4. All